Glaukos

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. 

CEO
Thomas William Burns
CEOThomas William Burns
Employees
1,094
Employees1,094
Headquarters
Aliso Viejo, California
HeadquartersAliso Viejo, California
Founded
1998
Founded1998
Employees
1,094
Employees1,094

GKOS Key Statistics

Market cap
9.00B
Market cap9.00B
Price-Earnings ratio
-46.47
Price-Earnings ratio-46.47
Dividend yield
Dividend yield
Average volume
1.03M
Average volume1.03M
High today
$154.12
High today$154.12
Low today
$149.45
Low today$149.45
Open price
$150.22
Open price$150.22
Volume
1.04M
Volume1.04M
52 Week high
$154.61
52 Week high$154.61
52 Week low
$73.16
52 Week low$73.16

Stock Snapshot

With a market cap of 9B, Glaukos(GKOS) trades at $152.96. The stock has a price-to-earnings ratio of -46.47.

As of 2026-07-09, Glaukos(GKOS) stock has fluctuated between $149.45 and $154.12. The current price stands at $152.96, placing the stock +2.3% above today's low and -0.8% off the high.

The Glaukos(GKOS)'s current trading volume is 1.04M, compared to an average daily volume of 1.03M.

During the past year, Glaukos(GKOS) stock moved between $73.16 at its lowest and $154.61 at its peak.

During the past year, Glaukos(GKOS) stock moved between $73.16 at its lowest and $154.61 at its peak.

GKOS News

Simply Wall St 4h
Is Glaukos’ Demodex Bet Quietly Reshaping Its Post-Glaucoma Ophthalmic Strategy?

In late June 2026, Glaukos Corporation announced it had fully enrolled 275 patients in a Phase 2 trial of GLK-321, a cream-based eyelid therapy using its iLutio...

Is Glaukos’ Demodex Bet Quietly Reshaping Its Post-Glaucoma Ophthalmic Strategy?
The Motley Fool 14h
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Should you stick with a diversified healthcare titan or a specialized high-growth challenger? Here is how Abbott Laboratories (ABT 0.70%) and Glaukos (GKOS +1.5...

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Analyst ratings

100%

of 14 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.